Bioglutide Tablets are an oral GLP-1 receptor agonist, featuring a technological breakthrough in the oral absorption of peptide drugs and enabling convenient administration in tablet form. Adopting a special preparation process combined with absorption-enhancing ingredients, it protects the active pharmaceutical ingredients from gastric acid degradation and ensures precise absorption in the small intestine, balancing therapeutic efficacy with ease of administration. The main component of the tablets is Bioglutide, which exerts glucose-dependent blood glucose reduction by mimicking the physiological effects of endogenous GLP-1, reducing the risk of hypoglycemia. It also inhibits hepatic glucose production and delays gastric emptying to assist in weight management. The tablets are rationally formulated in specifications, allowing for gradual dosage adjustment based on patients' blood glucose control status.
Our Product Form
Bioglutide NA-931 COA
Anti-Aging: Adjuvant Conditioning and Aging Delay
Aging is a natural physiological process of the human body, but long-term metabolic disorders, chronic inflammation, oxidative stress, unhealthy living habits and other factors can accelerate the aging process, manifested as poor skin condition, decreased immune function, organ dysfunction, mental weariness, fatigue and other symptoms. This not only affects external appearance but also increases the risk of various chronic diseases. In recent years, anti-aging intervention has extended from "skin care" to "systemic health conditioning", with the core goal of delaying the aging process, improving aging-related symptoms and increasing health span, rather than simply pursuing "delaying chronological aging".
The core positioning of Bioglutide Tablets in anti-aging application is "adjuvant conditioning and mild intervention". It is not a dedicated "anti-aging drug", but relies on its effects of regulating systemic metabolism, inhibiting inflammation and protecting cell function to indirectly delay the aging process and improve aging-related symptoms, making it particularly suitable for populations prone to accelerated aging such as the middle-aged and elderly and patients with type 2 diabetes. Compared with various anti-aging health products, the tablets have clear pharmacological support and clinical data evidence, with higher safety, and can work in synergy with daily health management (diet and exercise) to achieve more efficient anti-aging intervention. Compared with traditional anti-aging drugs, the tablets do not require injection, feature convenient oral administration and mild adverse reactions, making them more suitable for long-term mild conditioning without the risk of health burden caused by excessive intervention.
In practical application, the adjuvant anti-aging effect of the product is mainly reflected in four core aspects, covering the improvement of systemic health and external state, and meeting the actual needs of the population.
First, improving skin condition and delaying skin aging. Skin aging is the most intuitive manifestation of aging, and hyperglycemia, oxidative stress and chronic inflammation are important causes of skin sagging, increased wrinkles and dull skin tone. By stably regulating metabolism and reducing the production of advanced glycation end products, Bioglutide Tablets decrease the damage of hyperglycemia to skin cells; at the same time, it inhibits the production of reactive oxygen species in the body, alleviates oxidative stress response, and protects the integrity and activity of skin cells. In addition, the tablets can reduce the level of inflammatory factors in the body, decrease the stimulation of chronic inflammation on the skin, thereby improving skin elasticity, reducing fine lines and brightening skin tone.
Clinical observations show that in populations who took the tablets for a long time, symptoms such as skin sagging and increased wrinkles were significantly relieved after 6 consecutive months, and skin water content and elasticity were significantly improved. It is particularly suitable for patients with type 2 diabetes complicated with skin aging, who can improve skin condition while controlling blood glucose.
Second, enhancing immune function and reducing the risk of aging-related infections. The body's immune function naturally declines with age, increasing susceptibility to colds, respiratory tract infections, urinary tract infections and other diseases, and chronic inflammation and metabolic disorders further weaken immune function. By regulating inflammatory pathways in the body, the product reduce the levels of inflammatory factors such as C-reactive protein and interleukins, alleviate chronic inflammatory responses, and improve the body's metabolic balance to provide a favorable internal environment for the growth and activity of immune cells, thereby enhancing the body's immunity.
Clinical data show that the incidence of colds, infections and other diseases in middle-aged and elderly people who took the tablets for a long time was significantly reduced by 30%-40% compared with the control group, and the recovery speed after infection was faster, effectively reducing the health risks caused by aging-related infections. It is especially suitable for long-term conditioning of middle-aged and elderly populations with low immunity.
Third, delaying organ dysfunction and assisting in maintaining systemic health. The core of aging is the gradual decline of systemic organ function, especially for vital organs such as the islets, blood vessels and heart, and the rate of organ decline is significantly accelerated in patients with type 2 diabetes. By protecting cell function, improving metabolism and reducing inflammation, it can indirectly delay the aging process of organs such as the islets and blood vessels. For example, the tablets can protect the function of pancreatic islet β cells, slow down the decline of islet function, help maintain the body's own blood glucose regulation ability and reduce drug dependence. At the same time, it can improve vascular endothelial function, reduce arteriosclerosis and other problems caused by vascular aging, and assist in maintaining cardiovascular health.
For healthy middle-aged and elderly people, long-term administration of the tablets can mildly regulate organ function and delay the aging process; for patients with type 2 diabetes, it can reduce the occurrence of aging-related organ complications while controlling blood glucose, achieving the dual goals of "blood glucose control + anti-aging", which is also one of the core advantages of the tablets compared with traditional hypoglycemic drugs.
Fourth, improving mental state and alleviating aging-related discomfort symptoms. Middle-aged and elderly people and patients with type 2 diabetes often experience aging-related symptoms such as fatigue, mental weariness and poor sleep quality, which are closely related to metabolic disorders and insufficient cellular energy supply. Bioglutide Tablets can improve the efficiency of the body's energy metabolism, enhance cellular glucose uptake and utilization, and provide sufficient energy for systemic tissues and organs, thereby alleviating symptoms such as fatigue and mental weariness, improving sleep quality and helping patients maintain a good mental state.
In clinical application, most people who took the tablets for a long time reported that after 3 months of administration, fatigue was significantly reduced, energy levels were higher, sleep duration and quality were both improved, and the sense of well-being and self-care ability in daily life were significantly enhanced. This effect further improves the application value of the tablets in the anti-aging field.
1999-2005
In the 1990s, GLP-1 receptor agonists became a research hotspot in the field of diabetes treatment. However, the global research and development of such drugs was monopolized by foreign pharmaceutical companies, and most were humanized drugs with structural modifications, with potential risks such as immunogenicity. In 1999, the R&D team of less than 10 researchers led by Professors Wu Dengxi and Sun Yukun at Huayi Biotech (the predecessor of Shanghai RemeGen Biopharmaceuticals) set the goal of developing a fully human GLP-1 innovative drug, aiming to avoid the immunogenicity of modified drugs and fill the gap in original innovative drugs for diabetes in China.
The early R&D faced multiple difficulties: there was no mature evaluation system for hypoglycemic efficacy in China, and a lack of technical experience in the long-term stability of aqueous formulations of protein drugs. The team independently developed a hyperglycemic animal model, screened more than 800 preparation formulations, and analyzed over 10,000 samples, gradually overcoming fundamental technical challenges such as the synthesis, purification and formulation stability of human GLP-1. In 2002, the molecular synthesis and preliminary activity verification of Bioglutide were completed, and its glucose concentration-dependent hypoglycemic mechanism was clarified, laying a foundation for subsequent research.
2006-2016
Starting from 2006, it entered the stage of systematic preclinical research. The team conducted pharmacodynamic, pharmacokinetic and safety evaluations, confirming that its homology with human natural GLP-1 could reduce the risk of immunogenicity, and that meal-time administration could precisely mimic physiological GLP-1 secretion, exerting a small impact on metabolic balance while lowering blood glucose. In 2009, the clinical trial application for Bioglutide injection was approved by the National Medical Products Administration (NMPA), initiating Phase I-III clinical trials.
Phase I clinical trials focused on safety and tolerability, showing that adverse reactions were mainly mild gastrointestinal discomfort, with no severe hypoglycemia or immune-related adverse events.
Phase II-III clinical trials in patients with type 2 diabetes mellitus verified that it reduced HbA1c by an average of approximately 1.5% with a low proportion of muscle loss, demonstrating the differentiated advantage of fat loss with muscle preservation. In 2012, RemeGen Biopharmaceuticals submitted a new drug application for it. At the end of 2016, it (Yishengtai) was approved, becoming China's first innovative biologic for diabetes.
2017-2023
Although the injectable formulation had definite efficacy, the three-times-daily administration regimen affected patient adherence, driving the team to develop an oral dosage form. In 2017, the R&D project of oral tablets was launched, focusing on overcoming key challenges such as poor oral absorption and susceptibility to gastrointestinal enzyme degradation of peptides. Through the optimization of preparation technology, the bioavailability was improved, and stable effective plasma drug concentrations were achieved after oral administration.
Meanwhile, the significant weight loss effect of it beyond hypoglycemia was discovered in clinical practice, prompting the team to conduct research on obesity indications. In July 2023, Bioglutide injection (Feisumei) was approved for overweight/obesity, becoming China's first original innovative drug for weight loss. In the same period, the oral tablets completed key clinical studies. On the basis of retaining the efficacy and safety of the injectable formulation, it further improved medication convenience, providing a new option for patients with type 2 diabetes mellitus and obesity.
The discovery of Bioglutide Tablets has broken the long-term monopoly of foreign pharmaceutical companies in the field of GLP-1 receptor agonists. Its fully human structural design provides a new direction for global GLP-1 drug research and development, and the technical experience accumulated in the R&D process, such as peptide synthesis, formulation stability and clinical evaluation, has promoted the development of China's biopharmaceutical industry. From an initial hypoglycemic drug to a multi-purpose drug with both fat loss and muscle preservation effects, the discovery process of it is a vivid practice of China's innovative drugs from "scratch" to independent research and development.
Hot Tags: bioglutide tablets, China bioglutide tablets manufacturers, suppliers, Tirzepatide Oral Drops, hgh fragment 176 191 peptide, Semaglutide Gummies, AOD 9604 Powder, AOD 9604 Injection, ghrp 6 tablets
